GAMT joins the p53 network: Branching into metabolism

Cell Cycle

Volumn 9, Issue 9, 2010, Pages 1706-1710

  Ide, Takao ^a,c   Chu, Kiki ^a   Aaronson, Stuart A ^b   Lee, Sam W ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c SAGA UNIVERSITY   (Japan)

Author keywords

Cancer cell metabolism; Creatine metabolism; Fatty acid oxidation; GAMT; p53

Indexed keywords

ADENOSINE TRIPHOSPHATE; CREATINE; GUANIDINOACETATE METHYLTRANSFERASE; PROTEIN P53; REACTIVE OXYGEN METABOLITE;

APOPTOSIS; CANCER CELL; CANCER INHIBITION; CELL METABOLISM; CELL MOTILITY; CELL PROLIFERATION; CELL RESPIRATION; CELL SURVIVAL; ENERGY METABOLISM; FATTY ACID OXIDATION; GLYCOLYSIS; HUMAN; LIPID METABOLISM; METABOLIC STRESS; NONHUMAN; OXIDATIVE PHOSPHORYLATION; PROTEIN FUNCTION; REVIEW; UPREGULATION;

EID: 77953587752     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.9.9.11473     Document Type: Review

References (60)

1. Horn HF, Vousden KH. Coping with stress: multiple ways to activate p53. Oncogene 2007; 26:1306-16.
2. Clarke AR, Purdie CA, Harrison DJ, Morris RG, Bird CC, Hooper ML, et al. Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 1993; 362:849-52.
3. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW. Participation of p53 protein in the cellular response to DNA damage. Cancer Res 1991; 51:6304-11.
4. Kuerbitz SJ, Plunkett BS, Walsh WV, Kastan MB. Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci USA 1992; 89:7491-5.
5. Lane DP. Cancer. p53, guardian of the genome. Nature 1992; 358:15-6.
6. Lowe SW, Schmitt EM, Smith SW, Osborne BA, Jacks T. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 1993; 362:847-9.
7. Whibley C, Pharoah PD, Hollstein M. p53 polymorphisms: cancer implications. Nat Rev Cancer 2009; 9:95-107.
8. Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery CA Jr, Butel JS, et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 1992; 356:215-21.
9. Danilova N, Sakamoto KM, Lin S. p53 family in development. Mech Dev 2008; 125:919-31.
10. Hu W, Feng Z, Teresky AK, Levine AJ. p53 regulates maternal reproduction through LIF. Nature 2007; 450:721-4.
11. Ma W, Sung HJ, Park JY, Matoba S, Hwang PM. A pivotal role for p53: balancing aerobic respiration and glycolysis. J Bioenerg Biomembr 2007; 39:243-6.
12. Matheu A, Maraver A, Serrano M. The Arf/p53 pathway in cancer and aging. Cancer Res 2008; 68:6031-4.
13. Tasdemir E, Maiuri MC, Galluzzi L, Vitale I, Djavaheri-Mergny M, D'Amelio M, et al. Regulation of autophagy by cytoplasmic p53. Nat Cell Biol 2008; 10:676-87.
14. Vousden KH, Ryan KM. p53 and metabolism. Nat Rev Cancer 2009; 9:691-700.
15. Warburg O, Negelein E. Ueber den stoffwechsel der tumoren. Biochemische Zeitschrift 1924; 152:319-44.
16. Warburg O. On the origin of cancer cells. Science 1956; 123:309-14.
17. Jones RG, Thompson CB. Tumor suppressors and cell metabolism: a recipe for cancer growth. Genes Dev 2009; 23:537-48.
18. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009; 324:1029-33.
19. Schwartzenberg-Bar-Yoseph F, Armoni M, Karnieli E. The tumor suppressor p53 downregulates glucose transporters GLUT1 and GLUT4 gene expression. Cancer Res 2004; 64:2627-33. (Pubitemid 38523921)
20. Kawauchi K, Araki K, Tobiume K, Tanaka N. p53 regulates glucose metabolism through an IKK-NFkappaB pathway and inhibits cell transformation. Nat Cell Biol 2008; 10:611-8. (Pubitemid 351627381)
21. Schwartzenberg-Bar-Yoseph F, Armoni M, Karnieli E. The tumor suppressor p53 downregulates glucose transporters GLUT1 and GLUT4 gene expression. Cancer Res 2004; 64:2627-33. (Pubitemid 38523921)
22. Kondoh H, Lleonart ME, Gil J, Wang J, Degan P, Peters G, et al. Glycolytic enzymes can modulate cellular life span. Cancer Res 2005; 65:177-85. (Pubitemid 40070808)
23. Bensaad K, Tsuruta A, Selak MA, Vidal MN, Nakano K, Bartrons R, et al. TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell 2006; 126:107-20. (Pubitemid 44040989)
24. Matoba S, Kang JG, Patino WD, Wragg A, Boehm M, Gavrilova O, et al. p53 regulates mitochondrial respiration. Science 2006; 312:1650-3.
25. Vahsen N, Cande C, Briere JJ, Benit P, Joza N, Larochette N, et al. AIF deficiency compromises oxidative phosphorylation. EMBO J 2004; 23:4679-89.
26. Bensaad K, Vousden KH. p53: new roles in metabolism. Trends Cell Biol 2007; 17:286-91.
27. Jones RG, Plas DR, Kubek S, Buzzai M, Mu J, Xu Y, et al. AMP-activated protein kinase induces a p53-dependent metabolic checkpoint. Mol Cell 2005; 18:283-93.
28. Feng Z, Zhang H, Levine AJ, Jin S. The coordinate regulation of the p53 and mTOR pathways in cells. Proc Natl Acad Sci USA 2005; 102:8204-9.
29. Hardie DG, Pan DA. Regulation of fatty acid synthesis and oxidation by the AMP-activated protein kinase. Biochem Soc Trans 2002; 30:1064-70.
30. Wyss M, Kaddurah-Daouk R. Creatine and creatinine metabolism. Physiol Rev 2000; 80:1107-213.
31. Stockler S, Holzbach U, Hanefeld F, Marquardt I, Helms G, Requart M, et al. Creatine deficiency in the brain: a new, treatable inborn error of metabolism. Pediatr Res 1994; 36:409-13.
32. Item CB, Mercimek-Mahmutoglu S, Battini R, Edlinger-Horvat C, Stromberger C, Bodamer O, et al. Characterization of seven novel mutations in seven patients with GAMT deficiency. Hum Mutat 2004; 23:524.
33. Item CB, Stockler-Ipsiroglu S, Stromberger C, Muhl A, Alessandri MG, Bianchi MC, et al. Arginine:glycine amidinotransferase deficiency: the third inborn error of creatine metabolism in humans. Am J Hum Genet 2001; 69:1127-33. (Pubitemid 33015826)
34. Salomons GS, van Dooren SJ, Verhoeven NM, Cecil KM, Ball WS, Degrauw TJ, et al. X-linked creatine-transporter gene (SLC6A8) defect: a new creatine-deficiency syndrome. Am J Hum Genet 2001; 68:1497-500.
35. Schulze A. Creatine deficiency syndromes. Mol Cell Biochem 2003; 244:143-50.
36. Dinning JS, Seager LD. An elevated excretion of creatine associated with leukemia in mice. Science 1951; 114:502-3.
37. Gazdar AF, Zweig MH, Carney DN, Van Steirteghen AC, Baylin SB, Minna JD. Levels of creatine kinase and its BB isoenzyme in lung cancer specimens and cultures. Cancer Res 1981; 41:2773-7.
38. Joseph J, Cardesa A, Carreras J. Creatine kinase activity and isoenzymes in lung, colon and liver carcinomas. Br J Cancer 1997; 76:600-5. (Pubitemid 27354673)
39. Meffert G, Gellerich FN, Margreiter R, Wyss M. Elevated creatine kinase activity in primary hepatocellular carcinoma. BMC Gastroenterol 2005; 5:9.
40. Onda T, Uzawa K, Endo Y, Bukawa H, Yokoe H, Shibahara T, et al. Ubiquitous mitochondrial creatine kinase downregulated in oral squamous cell carcinoma. Br J Cancer 2006; 94:698-709. (Pubitemid 43361902)
41. Shatton JB, Morris HP, Weinhouse S. Creatine kinase activity and isozyme composition in normal tissues and neoplasms of rats and mice. Cancer Res 1979; 39:492-501. (Pubitemid 9095915)
42. Tsung SH. Creatine kinase activity and isoenzyme pattern in various normal tissues and neoplasms. Clin Chem 1983; 29:2040-3.
43. Zarghami N, Giai M, Yu H, Roagna R, Ponzone R, Katsaros D, et al. Creatine kinase BB isoenzyme levels in tumour cytosols and survival of breast cancer patients. Br J Cancer 1996; 73:386-90. (Pubitemid 26047519)
44. Patra S, Bera S, SinhaRoy S, Ghoshal S, Ray S, Basu A, et al. Progressive decrease of phosphocreatine, creatine and creatine kinase in skeletal muscle upon transformation to sarcoma. Febs J 2008; 275:3236-47. (Pubitemid 351743597)
45. Miller EE, Evans AE, Cohn M. Inhibition of rate of tumor growth by creatine and cyclocreatine. Proc Natl Acad Sci USA 1993; 90:3304-8.
46. Zhao J, Schmieg FI, Logsdon N, Freedman D, Simmons DT, Molloy GR. p53 binds to a novel recognition sequence in the proximal promoter of the rat muscle creatine kinase gene and activates its transcription. Oncogene 1996; 13:293-302. (Pubitemid 26334861)
47. Ide T, Brown-Endres L, Chu K, Ongusaha PP, Ohtsuka T, El-Deiry WS, et al. GAMT, a p53-inducible modulator of apoptosis, is critical for the adaptive response to nutrient stress. Mol Cell 2009; 36:379-92.
48. Vousden KH, Prived C. Blinded by the light: the growing complexity of p53. Cell 2009; 137:413-31.
49. Liu B, Chen Y, St. Clair DK. ROS and p53: a versatile partnership. Free Radic Biol Med 2008; 44:1529-35.
50. Miller EE, Evans AE, Cohn M. Inhibition of rate of tumor growth by creatine and cyclocreatine. Proc Natl Acad Sci USA 1993; 90:3304-8. (Pubitemid 23111354)
51. Medes G, Thomas A, Weinhouse S. Metabolism of neoplastic tissue: a study of lipid synthesis in neoplastic tissue slices in vitro. Cancer Res 1953; 12:27-9.
52. Ookhtens M, Kannan R, Lyon I, Baker N. Liver and adipose tissue contributions to newly formed fatty acids in an ascites tumor. Am J Physiol Regul Integr Comp Physiol 1984; 247:146-53.
53. Sabine JR, Abraham S, Chaikoff IL. Control of lipid metabolism in hepatomas: insensitivity of rate of fatty acid and cholesterol synthesis by mouse hepatome BW7756 to fasting and to feedback control. Cancer Res 1967; 27:793-9.
54. Bauer DE, Hatzivassiliou G, Zhao F, Andreadis C, Thompson CB. ATP citrate lyase is an important component of cell growth and transformation. Oncogene 2005; 24:6314-22.
55. Kuhajda FP, Piantadosi S, Pasternack GR. Haptoglobin-related protein (Hpr) epitopes in breast cancer as a predictor of recurrance of disease. N Engl J Med 1989; 3212:636-41.
56. Mazzarelli P, Pucci S, Bonanno E, Sesti F, Calvani M, Spagnoli LG. Carnitine palmitoyltransferase I in human carcinomas: a novel role in histone deacetylation? Cancer Biol Ther 2007; 6:1606-13.
57. Ursini-Siegel J, Rajput AB, Lu H, Sanguin-Gendreau V, Zuo D, Papavasiliou V, et al. Elevated expression of DecR1 impairs ErbB2/Neu-induced mammary tumor development. Mol Cell Biol 2007; 27:6361-71.
58. Wolfe RR. Metabolic interactions between glucose and fatty acids in humans. Am J Clin Nutr 1998; 67:519-26.
59. Jelluma N, Yang X, Stokoe D, Evan GI, Dansen TB, Haas-Kogan DA. Glucose withdrawal induces oxidative stress followed by apoptosis in glioblastoma cells but not in normal human astrocytes. Mol Cancer Res 2006; 4:319-30.
60. Delarue J, Magnan C. Free fatty acids and insulin resistance. Curr Opin Clin Nutr Metab Care 2007; 10:142-8.